跳至主要内容
临床试验/NL-OMON48551
NL-OMON48551已完成3 期

Peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults (Palisade) follow-on study. - PALISADE Follow-on Study

Aimmune Therapeutics UK Limited0 个研究点目标入组 4 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
4

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 64(—)

入选标准

  • 1. Completion of ARC003
  • 2. Written informed consent and/or assent from subjects/guardians as appropriate
  • 3. Use of effective birth control by female subjects of child-bearing potential

排除标准

  • 1. Early discontinuation from ARC003
  • 2. Meets any longitudinally applicable ARC003 exclusion criteria
  • 3. (Group 2 only) Failure to tolerate *443 mg cumulative of peanut protein with no or mild symptoms in the ARC Exit DBPCFC
  • 4. Any other condition that, in the opinion of the investigator, precludes participation for reasons of safety.

研究者

相似试验